AMO PHARMA
The company intends to use the funds to advance two clinical-stage pipeline assets targeting rare muscular and central nervous system disorders and to expand the AMO Pharma pipeline through acquisition of additional development-stage products.
AMO PHARMA
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2015-01-01
Address:
Wonersh, Surrey, United Kingdom
Country:
United Kingdom
Website Url:
http://www.amo-pharma.com
Total Employee:
1+
Status:
Active
Contact:
+4401483319070
Email Addresses:
[email protected]
Total Funding:
25 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Analytics Google Universal Analytics Apache Microsoft Exchange Online Office 365 Mail Google Maps Microsoft Azure DNS
Similar Organizations
Acasti Pharma
Acasti Pharma is an emerging biopharmaceutical company.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Basilea Pharmaceutica
Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Ocugen
Ocugen is a clinical stage biopharmaceutical company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Woodford Investment Management
Woodford Investment Management investment in Private Equity Round - AMO Pharma
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-14 | Julia Jones Joins AMO Pharma As Chief Financial Officer And Board Member |
Official Site Inspections
http://www.amo-pharma.com Semrush global rank: 5.05 M Semrush visits lastest month: 1.64 K
- Host name: cp4.names.co.uk
- IP address: 85.233.160.141
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
More informations about "AMO Pharma" on Search Engine
Leadership - AMO-pharma.com
About. Leadership. AMO Pharma is led by a team of industry professionals who combine extensive experience in biomedical science and research with proven skill in all phases of drug development and commercialization …See details»
About - AMO-pharma.com
AMO Pharma is dedicated to making a positive difference for people affected by serious and debilitating diseases, particularly rare or orphan diseases. To do this, we first work to …See details»
AMO Pharma - Crunchbase Company Profile & Funding
AMO Pharma is a privately held emerging biopharmaceutical company. Wonersh, Surrey, United Kingdom. 1-10. Private Equity. www.amo-pharma.com/ 72,394. Highlights. Total …See details»
AMO Pharma Company Profile 2024: Valuation, Funding
2015. Status. Private. Employees. 7. Latest Deal Type. Corporate. Latest Deal Amount. $35M. Investors. 2. General Information. Description. Operator of a privately held …See details»
AMO Pharma Completes Meeting with U.S. FDA and Outlines …
May 2, 2024 AMO Pharma Limited ("AMO Pharma"), a privately held clinical-stage specialty biopharmaceutical company focusing on rare genetic disorders with limited or …See details»
AMO Pharma Announces Collaboration with Population Health …
Feb 15, 2024 AMO Pharma Limited ("AMO Pharma"), a privately held clinical-stage specialty biopharmaceutical company focusing on rare genetic disorders with limited or …See details»
AMO Pharma Completes Meeting with U.S. FDA and Outlines …
May 2, 2024 AMO Pharma Completes Meeting with U.S. FDA and Outlines Plans to Advance Clinical Development of AMO-02 (tideglusib) in Treatment of Myotonic …See details»
AMO Pharma Company Profile - Craft
AMO Pharma is a biopharmaceutical company. The company aims to identify and advance therapies for the treatment of serious and debilitating diseases, including rare childhood …See details»
AMO Pharma Announces Affirming Data from REACH-CDM …
Sep 6, 2023 AMO Pharma is a clinical-stage specialty biopharmaceutical company working to identify and advance promising therapies for the treatment of serious and …See details»
AMO Pharma to conduct Phase III trial of DM1 treatment - Yahoo …
Fri, May 3, 2024, 6:22 AM 2 min read. AMO Pharma has announced its plans to initiate a Phase III clinical trial for its investigational therapy, AMO-02 (tideglusib), aimed at …See details»
AMO PHARMA LIMITED: FDA Grants Rare Pediatric Disease …
Nov 13, 2020 AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, childhood onset neurogenetic disorders with limited or no …See details»
Meet the DM Drug Developers: AMO Pharma - Myotonic …
We are excited to announce AMO Pharma will be moving forward with the REACH-CDM Clinical Trial for AMO-02 after the US FDA and Health Canada approved their recently …See details»
News - AMO-pharma.com
AMO Pharma is a biopharmaceutical company working to identify and advance promising therapies for the treatment of serious and debilitating diseases in patient populations with …See details»
AMO Pharma - Meet the DM Drug Developers - Myotonic …
AMO Pharma - Meet the DM Drug Developers | Myotonic Dystrophy Foundation. Presented on March 5th, 2021. In August 2020, AMO Pharma published the results of a Phase 2 …See details»
Meet the DM Drug Developers: AMO Pharma - myotonic.org
July 2023: AMO Pharma. Each month biotechnology, pharmaceutical and academic partners, large and small, working on treatments and a cure for myotonic dystrophy will …See details»
Investors - AMO-pharma.com
May 2, 2024 AMO Pharma is dedicated to making a positive difference for people affected by serious and debilitating diseases, particularly rare or orphan diseases. AMO Pharma …See details»
AMO Pharma - Funding, Financials, Valuation & Investors
AMO Pharma. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Funding Rounds 1. Total Funding Amount. Unlock for …See details»
Interim Results Released for AMO Pharma Clinical Trial
AMO Pharma has been conducting a Phase 2a clinical trial of Tideglusib (also known as AMO-02) for adolescents and adults with congenital myotonic dystrophy. Tideglusib is an …See details»
News - AMO-pharma.com
AMO Pharma Announces Completion of Treatment of Last Patient in Pivotal REACH-CDM Clinical Trial in Myotonic Dystrophy. News Release – Feb 27, 2023. AMO Pharma …See details»
Amolyt Pharma Enters into Definitive Agreement to be Acquired …
Mar 14, 2024 Lyon, France, and Cambridge, MA, March 14, 2024 — Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic …See details»